BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Trading 07-17 10:08:13 EDT

310.43

-6.99

-2.20%

High311.24	Low303.08	Vol55.14K
Open307.59	D1 Closing317.42	Amplitude2.57%
Mkt Cap36.94B	Tradable Cap26.53B	Total Shares119.00M
T/O17.00M	T/O Rate0.06%	Tradable Shares85.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":310.43,"timestamp":1784297290035,"preClose":317.42,"halted":0,"volume":55139,"delay":0,"changeRate":-0.02202129670468152,"floatShares":85446200,"shares":119000000,"eps":4.404108,"marketStatus":"Trading","change":-6.99,"latestTime":"07-17 10:08:13 EDT","open":307.59,"high":311.24,"low":303.08,"amount":17001074.0368,"amplitude":0.025707,"askPrice":310.55,"askSize":20,"bidPrice":310.32,"bidSize":113,"shortable":3,"etf":0,"ttmEps":4.404108,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784318400000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":317.42,"preHourTrading":{"tag":"盘前","latestPrice":307.52,"preClose":317.42,"latestTime":"09:29 EDT","volume":4123,"amount":1297799.43118,"timestamp":1784294995390,"change":-9.9,"changeRate":-0.031189,"amplitude":0.010081},"postHourTrading":{"tag":"盘后","latestPrice":317.42,"preClose":317.42,"latestTime":"19:56 EDT","volume":1180,"amount":374509.9801,"timestamp":1784246211483,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.152514,"impliedVol":0.4187,"impliedVolPercentile":0.3665},"requestUrl":"/m/hq/s/ONC/wiki","defaultTab":"wiki","newsList":[{"id":"2652139404","title":"Press Release: Beone Medicines to Announce Second Quarter 2026 Financial Results on August 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2652139404","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652139404?lang=en_us&edition=fundamental","pubTime":"2026-07-17 18:02","pubTimestamp":1784282520,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif.--(BUSINESS WIRE)--July 17, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on We","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","ONC","BK4588","BK4139","BK4585","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651544933","title":"BeOne Medicines (ONC) Stock Looks Expensive Even With Strong Pipeline Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2651544933","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651544933?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:33","pubTimestamp":1784198003,"startTime":"0","endTime":"0","summary":"BeOne Medicines has delivered a 61.1% return over the past three years, yet its current valuation screens as overvalued on market multiples and only middling on broader checks. This raises the question of how much optimism is already reflected in the share price.\n\nA 61.1% three year return suggests investors have already priced in a meaningful amount of good news for BeOne Medicines.\nRecent analyst upgrades tied to the chronic lymphocytic leukemia franchise and solid tumor pipeline can...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-stock-looks-expensive-even-with-strong-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-stock-looks-expensive-even-with-strong-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4526","BK4588","BK4139","ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482014","title":"How Chemotherapy-Free Phase 3 MCL Success At BeOne Medicines (ONC) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482014","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651482014?lang=en_us&edition=fundamental","pubTime":"2026-07-15 05:23","pubTimestamp":1784064190,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. recently reported positive topline results from its Phase 3 MANGROVE trial, where BRUKINSA (zanubrutinib) plus rituximab significantly improved progression-free survival versus bendamustine plus rituximab in previously untreated mantle cell lymphoma.\nThis is the first global Phase 3 study to show a chemotherapy-free, rituximab maintenance-free regimen can match or exceed standard chemoimmunotherapy, potentially sparing patients around two years of infusion treatment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/how-chemotherapy-free-phase-3-mcl-success-at-beone-medicines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/how-chemotherapy-free-phase-3-mcl-success-at-beone-medicines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MDCO","ONC","BK4585","BK4526","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651150175","title":"BeOne Medicines (ONC) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2651150175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651150175?lang=en_us&edition=fundamental","pubTime":"2026-07-14 16:37","pubTimestamp":1784018241,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $403.00. Darout covers th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4588","BK4585","ONC","BK4526","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650750489","title":"BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2650750489","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650750489?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:31","pubTimestamp":1783614692,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines is running a Phase 1 study in healthy adults to test ho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-sonrotoclax-formulation-study-signaling-progress-in-onc-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-sonrotoclax-formulation-study-signaling-progress-in-onc-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BK4097","MDCO","PRGS","ONC","BK4526","LU2065732104.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650978219","title":"BeOne Medicines treatment of pancreatic cancer granted orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2650978219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650978219?lang=en_us&edition=fundamental","pubTime":"2026-07-09 23:00","pubTimestamp":1783609213,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC)’ MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-treatment-of-pancreatic-cancer-granted-orphan-status-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-treatment-of-pancreatic-cancer-granted-orphan-status-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCO","BK4526","BK4585","ONC","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124370507","title":"BEIGENE Awards Aggregate 33,400 Restricted Stock Units Represented by American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124370507","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124370507?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:06","pubTimestamp":1783501565,"startTime":"0","endTime":"0","summary":"BEIGENE (HKEX: 06160) has announced that on July 2, 2026, the Compensation Committee of the Board of Directors, pursuant to the terms of the 2016 Option and Incentive Plan, granted a total of 33,400...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK1500","KURE","688235","BK1161","BK4588","06160","BK4139","BK1588","BK4585","LU2328871848.SGD","ONC","LU0307460666.USD","BK0239","LU1719994722.HKD","LU1770034418.SGD","LU0588546209.SGD","BK1583","LU1251922891.USD","BK4526","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163772490","title":"BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1163772490","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163772490?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:43","pubTimestamp":1783042997,"startTime":"0","endTime":"0","summary":"Shares of BEIGENE (HKEX: 06160) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.The increase follows the company's...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","BK1588","BK1161","BK4139","688235","LU1303224171.USD","BK4588","LU1251922891.USD","LU0588546209.SGD","LU1719994722.HKD","ONC","BK4585","06160","BK4526","VXUS","LU0307460666.USD","LU1770034418.SGD","BK1583","BK0239","LU1969619763.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510936","title":"Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648510936?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:40","pubTimestamp":1782906024,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-beone-medicines-onc-and-zevra-therapeutics-zvra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-beone-medicines-onc-and-zevra-therapeutics-zvra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZVRA","LU0154245673.USD","LU0029874061.USD","BK4139","BK4532","LU0320765992.SGD","IE00BN0W2W23.USD","MDCO","JAZZ","LU0128526141.USD","XLV","LABU","ONC","LU0109394709.USD","LU0889565916.HKD","LU0823416689.USD","BK4137","LU0154245756.USD","IE00BN0W2T93.GBP","BK4588","BK4581","BK4526","HCSG","IE00BN0W2V16.EUR","XBI","BK4007","BK4533","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183010146","title":"BEIGENE Reports Positive Phase 3 Trial Results for BRUKINSA® in First-Line Treatment of Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1183010146","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183010146?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:12","pubTimestamp":1782828767,"startTime":"0","endTime":"0","summary":"BEIGENE announced positive results from the MANGROVE Phase 3 clinical trial (BGB-3111-306;NCT04002297).The study evaluated its foundational, self-developed BTK inhibitor, BRUKINSA® (zanubrutinib),...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK4585","LU1969619763.USD","LU0588546209.SGD","688235","LU1770034418.SGD","BK4526","06160","BK4139","LU1251922891.USD","BK1588","BK1583","BK4588","LU1719994722.HKD","ONC","BK0239","BK1161","LU1303224171.USD","LU0307460666.USD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453719","title":"BeOne Medicines' Potential Chemotherapy-Free Lymphoma Treatment Meets Primary Endpoint in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453719?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816030,"startTime":"0","endTime":"0","summary":"BeOne Medicines'  Brukinsa met its primary endpoint of progression-free survival in a phase 3 study evaluating the drug as a potential treatment in combination with rituximab for mantle cell lymphoma, the company said Tuesday.The chemotherapy-free drug combination showed \"a highly statistically significant and clinically meaningful improvement\" versus standard of care, the company said.The safety profile was consistent with that of both medicines, the company said.Mantle cell lymphoma is a rare and typically aggressive type of B-cell non-Hodgkin lymphoma, mostly affecting older adults, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","MDCO","ONC","BK4139","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647327725","title":"Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2647327725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647327725?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:33","pubTimestamp":1782725580,"startTime":"0","endTime":"0","summary":"Chinese biopharma stocks rallied on Monday, as investors moved away from artificial-intelligence stocks amid concerns over overstretched valuations.Shares of BeOne Medicines led gains among biopharma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","ONC","ARTY","00241","AIPO","ISBC","LU1226287529.USD","688180","BK1161","LU2328871848.SGD","06618","BK4585","LU1993786604.SGD","LU0456827905.SGD","LU2039709279.SGD","01093","XBI","600276","LU1808992512.USD","LU1008478684.HKD","BK1191","86618","LU1303224171.USD","BK1189","HCSG","BK1502","01801","BK0012","IE00BZ08YS42.EUR","01877","02315","BK4137","LABU","LU0405327494.USD","LU1807302812.USD","603259","BK1571","AGIX","CHAT","LU1255011170.USD","BK0028","LU0315179316.USD","IE00BPRC5H50.USD","09637","BK0216","LU1251922891.USD","BK0196","BK0239","BK1583","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125815089","title":"BEIGENE Subsidiary to Pay Approximately 446 Million Yuan in Back Taxes, No Penalty Involved","url":"https://stock-news.laohu8.com/highlight/detail?id=1125815089","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125815089?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:08","pubTimestamp":1782468514,"startTime":"0","endTime":"0","summary":"BEIGENE (ASX: 06160) has announced that a wholly-owned subsidiary in China has received and agreed to a notice from local tax authorities regarding adjustments to previously filed tax returns.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","688235","BK4588","LU1719994722.HKD","LU1770034418.SGD","BK0239","LU1303224171.USD","LU0588546209.SGD","LU1251922891.USD","BK1583","BK4139","LU0307460666.USD","BK1500","BK4526","BK1161","ONC","BK1588","BK4585","LU1969619763.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646802037","title":"BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802037?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405082,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running an observational study called “A Real-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4526","MDCO","BK4585","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808016","title":"BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808016?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800347,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) investors are watching a new update on a BeiGene ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4139","BK4588","ISBC","BK4585","BK4211","ONC","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644809090","title":"BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644809090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644809090?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800331,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1a/1b study, officially titled “Phase 1a/1b Randomized Study ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4139","BK4585","BK4211","BK4588","BGB","ISBC","BK4526","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162658338","title":"BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1162658338","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162658338?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:21","pubTimestamp":1781788869,"startTime":"0","endTime":"0","summary":"The pharmaceutical company BEIGENE (06160) has disclosed the granting of share-based awards to certain recipients.On June 11, 2026, the board of directors, the compensation committee, and/or the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","LU1770034418.SGD","06160","BK4588","BK1161","BK4526","BK4585","LU0307460666.USD","LU1969619763.USD","BK4139","LU2328871848.SGD","BK1583","LU0588546209.SGD","LU1719994722.HKD","BK1588","BK1500","BK0239","LU1251922891.USD","LU1303224171.USD","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644370681","title":"BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2644370681","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644370681?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:39","pubTimestamp":1781771940,"startTime":"0","endTime":"0","summary":"0839 GMT - BeOne Medicine's revenue is forecast to reach $6.5 billion in 2026, driven by flagship cancer drug Brukinsa, which helped turn its operating margins positive last year, Morningstar analyst Kai Wang says. He sees the stock as undervalued, citing potential sales growth of its chronic lymphocytic leukemia treatment Brukinsa and its other core product Beqalzi, which is projected to generate $1 billion in sales by 2035. Wang estimates margin expansion of 400 basis points over the long term, as Brukinsa continues to scale out and capture more market share. Beyond 2026, Morningstar forecasts Brukinsa revenue growth in the high teens annually before slowing to 6% by 2032, when its patent expires. It initiates coverage of BeOne's H-shares with a fair value estimate of HK$214. The stock closed at HK$163.70. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4139","ONC","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644728385","title":"BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2644728385","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644728385?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:32","pubTimestamp":1781713967,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running a Phase 1 study called “An Open-Label,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCO","ONC","BGB","BK4588","BK4526","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643276720","title":"BeOne Medicines (ONC) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2643276720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643276720?lang=en_us&edition=fundamental","pubTime":"2026-06-15 16:37","pubTimestamp":1781512665,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4526","BK4588","BK4585","BK4139","MDCO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0482},{"period":"1month","weight":0.2027},{"period":"3month","weight":-0.0199},{"period":"6month","weight":-0.0614},{"period":"1year","weight":0.1371},{"period":"ytd","weight":0.0448}],"compareEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.0854},{"period":"1year","weight":0.2027},{"period":"ytd","weight":0.1009}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.363636,"avgChangeRate":0.018832},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.019621},{"month":6,"riseRate":0.454545,"avgChangeRate":0.010403},{"month":7,"riseRate":0.818182,"avgChangeRate":0.144178},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","securityTypeName":"DR","adrRate":"1:13"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction